Incyte chief executive PaulFriedman says the company hopes to get data from a final-stage myelofibrosis trial in December that could lead to approval next year.
But Max PaulFriedman, history professor at American University, dismisses it as "a term that's been used to characterise almost any disagreement with US policy of the day".